Extracorporeal CO2-removal with a heparin coated artificial lung
Jeroen PetersPeter RadermacherMelissa KuntzK. A. RosenbauerM. BreulmannKarl‐Friedrich BürrigHans‐Bernd HopfRolf RossaintH. D. SchultePetter OlssonK. J. Falke
30
Citation
14
Reference
10
Related Paper
Citation Trend
Keywords:
Extracorporeal
Artificial lung
Extracorporeal circulation
Activated clotting time
The accurate assessment of coagulation status is an important part of interventional procedures performed in the cardiac catheterization laboratory. While the traditional clinical means of assessing heparin anticoagulation has been with the activated partial thromboplastin time (APTT), the activated coagulation time (ACT) has come into widespread use in the catheterization laboratory as an assay of whole blood clotting time which can be performed rapidly at the bedside. The purpose of the present study was to (1) assess the anticoagulant effect of a 10,000 U bolus of heparin in PTCA patients and (2) document the relationship between ACTs and APTTs in a subset of these patients. Baseline and postheparin ACTs were measured using a HemoTec coagulation timer in 545 unselected PTCA patients. The average baseline ACT was 120 +/- 22 sec. After a 10,000 U bolus of heparin the average ACT was 249 +/- 44 sec; 58% of patients had an ACT less than 250 sec, 17% had an ACT between 250 and 275 sec, 12% had an ACT between 275 and 300 sec, and 13% had an ACT greater than 300 sec. A total of 175 paired ACT and APTT measurements were obtained in a random subset of these patients at baseline, after heparinization, and at 4-6 hr intervals after the procedure. The APTT was limited by absolute upper and lower limits of 150 and 22 sec; there were no such limits on the ACT. When limiting values were excluded, there was a strong overall correlation between ACT and APTT measurements (r = 0.92, p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
Activated clotting time
Bolus (digestion)
Coagulation testing
Cardiac catheterization
Cite
Citations (87)
Introduction: Historically, the activated clotting time (ACT) has been the preferred monitoring test of the heparin effect in extracorporeal membrane oxygenation (ECMO) patients. However, few adult studies have evaluated its correlation to the heparin dose or other monitoring tests, such as the activated partial thromboplastin time (aPTT). This retrospective study sought to evaluate the correlation between the heparin dose and these monitoring tests. Methods: Patients administered a heparin drip during ECMO were included in this study. The primary endpoints were the correlation between heparin dose and ACT or aPTT and the relationship between paired ACT and aPTT samples. Results: Forty-six patients met the criteria for study inclusion. A better correlation was observed for heparin dose and aPTT (Pearson product-moment correlation coefficient ( r) = 0.43 – 0.54) versus ACT ( r = 0.11 – 0.14). Among the paired sample data, ACT values did not differ significantly between Groups two (aPTT 60 – 75 seconds) and three (aPTT >75 seconds). Conclusion: The heparin dose correlated better with aPTT relative to ACT and, thus, may be considered a more effective tool for the dosing of heparin in adult ECMO patients. Paired ACT and aPTT sample data suggested a poor relationship between these two anticoagulant monitoring tests.
Activated clotting time
Thrombin time
Coagulation testing
Clotting time
Prothrombin time
Cite
Citations (69)
Activated clotting time
Clotting time
Cite
Citations (21)
Heparin levels and ACT were followed during open heart surgery in lo patients. Heparin was assayed by an amidolytic method using substrate S-2222. ACT was determined with an automated method using celite and glass beads as activators of coagulation. Neither the hemodilution nor the depletion of platelets observed during extracorporeal circulation seemed to influence the ACT. An excellent correlation between the ACT and the actual heparin level was found in each patient with coefficients of correlation ranging from 0.73 – 0.97. A slightly better correlation was noticed for values of ACT below 600 seconds. It was concluded that the ACT is a valuable and reliable tool in control of heparinisation during open heart surgery.
Extracorporeal circulation
Activated clotting time
Extracorporeal
Positive correlation
Cite
Citations (0)
OBJECTIVE: To evaluate the clinical safety of heparin titration and the procedural cost of anticoagulation measurement using bedside low-range activated clotting time. DESIGN: Quasi-experimental study using data gathered through retrospective record review. SETTING: Coronary care, medical intensive care and telemetry units of a community hospital. SUBJECTS: Sample of 102 patients undergoing elective percutaneous transluminal coronary angioplasty. INTERVENTION: Intravenous heparin therapy was titrated using low-range activated clotting time in 51 percutaneous transluminal coronary angioplasty patients. Data from this group were compared to a matched sample of 51 angioplasty patients whose intravenous heparin therapy was titrated using activated partial thromboplastin time. RESULTS: No differences in procedural, early or late complications were found between the groups. The cost of managing heparin therapy with low-range activated clotting time was less than with activated partial thromboplastin time. CONCLUSION: These results suggest that titrating heparin therapy based on bedside low-range activated clotting time for the angioplasty patients in this sample was as safe as with activated partial thromboplastin time. Use of bedside low-range activated clotting time saved money for the hospital.
Activated clotting time
Clotting time
Cite
Citations (4)
Aims: Aim of this study was to determine the accuracy of an ACT bed-side-test for heparin monitoring in patients under cardiac-assist-device-support. The correlation between activated clotting time (ACT) and activated partial thromboplastin time (aPTT) was determined.
Activated clotting time
Clotting time
Prothrombin time
Cite
Citations (0)
To determine whether activated partial thromboplastin times are a better heparin management tool than activated clotting times in pediatric extracorporeal membrane oxygenation.A single-center retrospective analysis of perfusion and patient records.Academic pediatric tertiary care center.Pediatric patients (<21 yrs old) requiring extracorporeal membrane oxygenation support initiated at Children's Hospital of Pittsburgh.None.Point-of-care activated clotting time and activated partial thromboplastin time values, clinical laboratory activated partial thromboplastin time values, weight-normalized heparin administration (units/kg/hr), and reported outcomes were collected for pediatric patients treated for cardiac and/or respiratory failure with extracorporeal membrane oxygenation. Spearman's ranked correlations were performed for each coagulation test compared to heparin dosage. The Bland-Altman test was used to determine the validity of the point-of-care activated partial thromboplastin time. Hazard analysis was conducted for outcomes and complications for patients whose heparin management was based on the clinical laboratory activated partial thromboplastin time or the activated clotting time. Only the clinical laboratory activated partial thromboplastin time showed a correlation (ρ = 0.40 vs. ρ = -0.04 for activated clotting time) with the heparin administration (units/kg/hr). Point-of-care activated partial thromboplastin time and activated partial thromboplastin time values correlated well (ρ = 0.76), with <5% of samples showing a difference outside 2 SDs, but differences in their absolute values (Δactivated partial thromboplastin time = 100 secs) preclude them from being interchangeable measures. Furthermore, despite no effective change in the mean activated clotting time, cardiac patients showed a significantly improved correlation to heparin dose for all coagulation tests (e.g., point-of-care activated partial thromboplastin time ρ = 0.60). Management of patients with the clinical laboratory activated partial thromboplastin time did not significantly affect patient survival rates but did significantly reduce bleeding complications and significantly increased clotting in the extracorporeal membrane oxygenation circuit. A hazard analysis demonstrated that bleeding complications were associated with an increased risk of mortality, whereas clotting complications in the extracorporeal membrane oxygenation circuit were not.The activated clotting time is not an accurate monitoring tool for heparin management in pediatricextracorporeal membrane oxygenation. The point-of-care activated partial thromboplastin time correlates well with the clinical laboratory activated partial thromboplastin time but cannot be substituted for the clinical laboratory activated partial thromboplastin time values. Management of pediatric extracorporeal membrane oxygenation patients with the clinical laboratory activated partial thromboplastin time reduced bleeding complications which are associated with increases in mortality.
Activated clotting time
Prothrombin time
Thrombin time
Clotting time
Thromboplastin
Cite
Citations (70)
Restricted accessAbstractFirst published August 2001Cardiopulmonary Bypass - Extracorporeal circulation - Artificial lung - Artificial LiverVolume 24, Issue 8https://doi.org/10.1177/039139880102400833
Extracorporeal circulation
Artificial lung
Artificial liver
Extracorporeal
Circulation (fluid dynamics)
Heart-Lung Machine
Artificial heart
Cite
Citations (0)
Activated clotting time
Bolus (digestion)
Prothrombin time
Coagulation testing
Clotting time
Cite
Citations (8)
To assess the utility of activated clotting time, activated partial thromboplastin time, and anti-Factor Xa assay for the monitoring and dosing of heparin in pediatric patients requiring support with extracorporeal membrane oxygenation.Retrospective chart review.PICU in a single, tertiary care, academic children's hospital.Seventeen patients (age 1 d to 13.9 yr, median 0.83 yr) managed on pulmonary and cardiac extracorporeal membrane oxygenation between March 2010 and August 2012 by a single surgeon.None.Twice daily measurements of anti-Factor Xa assay, activated clotting time, and activated partial thromboplastin time were determined from the same blood specimen. Data were analyzed using SAS system v9.2. Fourteen patients (82.4%) were successfully weaned from extracorporeal membrane oxygenation and 12 (70.6%) were discharged from the hospital. Pearson correlations were used to compare heparin dose and activated clotting time, activated partial thromboplastin time, and anti-Factor Xa assay. Analysis showed negative Pearson correlations in 11 of 17 patients between the activated clotting time and heparin, as compared with seven of 17 for activated partial thromboplastin time and only one for heparin and anti-Factor Xa assay. Only four patients had moderate to strong positive correlations between activated clotting time and heparin as compared with a moderate to strong positive correlation in 10 patients for anti-Factor Xa assay and heparin.The anti-Factor Xa assay correlated better with heparin dosing than activated clotting time or activated partial thromboplastin time. Activated clotting time has a poor correlation to heparin doses commonly associated with extracorporeal membrane oxygenation. In pediatric extracorporeal membrane oxygenation, anti-Factor Xa assay may be a more valuable monitor of heparin administration.
Activated clotting time
Clotting time
Prothrombin time
Clotting factor
Thrombin time
Cite
Citations (127)